Table 2 Clinical characteristics of the eyes included in the analysis

From: Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy

  Treatment administered
PDT + anti-VEGF PDT anti-VEGF None
Total number of eyes 24 9 8 7
Mean initial BCVA ( ± SD) 65.5 ± 8.9 letters 74.9 ± 5.3 letters 65.5 ± 7.4 letters 77.9 ± 13.2 letters
Lens status
  Phakic 16a 8 7a 4a
  Pseudophakic 8 1 1 3
Lesion site     
  Macular 12 3 6 1
  Juxtapapillary 10 6 2 6
  Bothb 2 0 0 0
Subretinal hemorrhage Anti-VEGF agent used 15/24c 2/9 4/8 4/7
  Ranibizumab 2 N/A 0 N/A
  Aflibercept 21 N/A 8 N/A
  Bothd 1 N/A 0 N/A
Previous treatment
  PDT 2 1 0 0
  Anti-VEGF 3 2 0 0
  Other 0 0 1e 0
  None 20 7 7 7
Median follow-up (range) 83.3 weeks (8.1–254.7) 66.7 weeks (33.4–130.4) 108.8 weeks (61.6–153.7) 47.1 weeks (12.3–140.0)
  1. BCVA best corrected visual acuity, SD standard deviation, N/A not applicable
  2. aOne eye in each of these groups had cataract surgery following initial assessment and before final follow-up
  3. bPolyp identified at the junction between macula and juxtapapillary area
  4. cOne patient developed submacular hemorrhage after initial presentation
  5. dTreatment initiated with ranibizumab, subsequently switched to aflibercept
  6. eLarge submacular hemorrhage treated as an emergency with intravitreal tissue plasminogen activator and bevacizumab